Tushar Tarun
Cardiovascular Disease · Little Rock, ARNPI 1497160386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,695 of the $4,352 with a category attached, or 61.9%. 12 manufacturers reported payments, led by Abbott at 38.8% of the total. Reporting peaked in 2019 at $2,409 and has fallen 90.8% since, to $221 in 2025.
Across 64 payments — averaging $68.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$2K
- Amgen$246
- Heartflow, Inc.$130
- AstraZeneca$121
- Cvrx, Inc.$117
- plus $376 from 6 others
What the payments were for
- Travel & lodging$1,09925%
- Food & beverage$2,69562%
- Education$51212%
- Gifts$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $1,690 |
| Medtronic(2 entities) | 20 | $1,671 |
| Amgen(2 entities) | 9 | $246 |
| Heartflow, Inc. | 1 | $130 |
| AstraZeneca | 2 | $121 |
| Cvrx, Inc. | 1 | $117 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $110 |
| Boston Scientific | 1 | $93 |
| Otsuka America Pharmaceutical, Inc. | 1 | $68 |
| Chiesi USA, Inc. | 2 | $59 |
| Edwards Lifesciences | 1 | $33 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,352 in reported general payments places this provider in the 55th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $30,014 |
| JardianceEmpagliflozin | 22 | $15,150 |
| EntrestoSacubitril/Valsartan | 13 | $8,797 |
| Metoprolol Succinate | 110 | $1,126 |
| Atorvastatin Calcium | 49 | $587 |
| Rosuvastatin Calcium | 39 | $570 |
| Ezetimibe | 27 | $427 |
| Chlorthalidone | 15 | $419 |
| Losartan Potassium | 41 | $326 |
| Carvedilol | 59 | $318 |
| Bumetanide | 16 | $299 |
| Spironolactone | 52 | $227 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $224 |
| Potassium Chloride | 20 | $190 |
| Furosemide | 45 | $167 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.